Compare DoorDash Inc (DASH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? DoorDash Inc trades at $192.17 (market cap $82.86B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DASH | VRTX | |
|---|---|---|
Market Cap | $82.86B | $128.16B |
Volume | 2,006,669 | 806,603 |
Sector | Media | Health |
52-Week High | $275.44 | $557.96 |
52-Week Low | $146.60 | $407.37 |
Typical Hold Time | 59 Days | 120 Days |
Enterprise Value | $80.82B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $191.71, down 0.99% on the day, with strong analyst support showing 75% buy ratings and a $255.80 consensus price target. The company demonstrates robust revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with net income of $935M. Recent innovations include AI-powered text ordering and drone delivery expansion, though mixed quarterly earnings and a fraud investigation present near-term headwinds.
The outlook remains positive given DoorDash's market leadership and expansion into retail delivery, but investors face risks from competitive pressures, regulatory scrutiny, and elevated valuation multiples. With current price near analyst targets and technical indicators showing bullish momentum, the stock offers growth potential balanced against execution risks in a competitive delivery market.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
